Healthcare Industry News: Age-related Macular Degeneration
News Release - January 31, 2006
OptiMedica(R) Corporation Announces Introduction of the PASCAL(R) Pattern Scan Laser PhotocoagulatorSANTA CLARA, Calif., Jan. 31 (HSMN NewsFeed) -- OptiMedica® Corporation announces the introduction of a new innovative photocoagulator recently demonstrated at the Macula 2006 Symposium in New York City and the Hawaiian Eye/Retina 2006 Annual Meeting held in Maui. In 2005, the company received FDA clearance for its PASCAL® laser for use in standard photocoagulation procedures. Pan-retinal photocoagulation for proliferative diabetic retinopathy and macular grid for diabetic macular edema are the primary applications.
The name PASCAL is an acronym for pattern scan laser. The 532 nm laser photocoagulator is a proprietary semi-automated pattern generation method. The pattern array options include single spot, square arrays, octants, quadrants, macular grid and arcs. As many as 25 spots may be delivered in 0.5 seconds.
The PASCAL Method of Photocoagulation provides significantly enhanced benefits to both the physician and patient while remaining consistent with standard protocols. This method enables ophthalmologists to provide more rapid, precise, and safe treatment.
The fully integrated system incorporates sophisticated advancements in ergonomics as well as controls and displays, like the LCD touch-screen and the dual slit lamp mounted electronic micromanipulators and rotary power controls.
Located in Santa Clara, California, the Company was founded in January 2004 to develop a radically new technology for the treatment of ocular disease. Initially developed at Stanford University, and exclusively licensed to the OptiMedica Corporation, the PASCAL® Method of Photocoagulation is used to treat a variety of retinal conditions including diabetic retinopathy, Age-related Macular Degeneration, and retinal vascular occlusive disease. The PASCAL Photocoagulator provides significantly improved performance for the physician and an enhanced therapeutic experience for the patient. For more information please log on to www.optimedica.com
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.